Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Year After It Wins Ratiopharm, Teva Reaps Rewards in Europe

Executive Summary

For innovator firms, Europe has been about surviving multiple price cuts and government austerity measures. For generics firms, it has become a land of opportunity, where 2011 growth will outpace the overall pharmaceutical market.

Related Content

Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015
Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines
EU Drug Pricing: The Only Way Is Down
Unified European Patent A Step Closer, But Unified Court Has A Ways Ro Go
Pfizer's European Lipitor Patent Extension: Likely In Some EU Countries
Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe
Pricing Experiments: Pharmas Get Creative in Germany
Pricing Experiments: Pharmas Get Creative in Germany





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts